NO20081951L - Milnacipran for langtidsbehandling av fibromyalgisyndrom - Google Patents

Milnacipran for langtidsbehandling av fibromyalgisyndrom

Info

Publication number
NO20081951L
NO20081951L NO20081951A NO20081951A NO20081951L NO 20081951 L NO20081951 L NO 20081951L NO 20081951 A NO20081951 A NO 20081951A NO 20081951 A NO20081951 A NO 20081951A NO 20081951 L NO20081951 L NO 20081951L
Authority
NO
Norway
Prior art keywords
long
term treatment
milnacipran
fibromyalgia syndrome
fms
Prior art date
Application number
NO20081951A
Other languages
English (en)
Inventor
Jay D Kranzler
Srinivas G Rao
Michael Gendreau
Original Assignee
Cypress Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37900431&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081951(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cypress Bioscience Inc filed Critical Cypress Bioscience Inc
Publication of NO20081951L publication Critical patent/NO20081951L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Foreliggende oppfinnelse er rettet på fremgangsmåte for å tilveiebringe langtidsbehandling av fibromyalgi syndrom (FMS) ved administrering av en dobbelt reopptaksinhibitor til en pasient med FMS. Mer spesielt er foreliggende oppfinnelse rettet på langtidsbehandling av FMS ved administrering av noradrenalin serotonin reopptaksinhibitor (NSRI) til en pasient med FMS.
NO20081951A 2005-09-28 2008-04-23 Milnacipran for langtidsbehandling av fibromyalgisyndrom NO20081951L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72172205P 2005-09-28 2005-09-28
PCT/US2006/037714 WO2007038620A2 (en) 2005-09-28 2006-09-27 Milnacipran for the long-term treatment of fibromyalgia syndrome

Publications (1)

Publication Number Publication Date
NO20081951L true NO20081951L (no) 2008-04-23

Family

ID=37900431

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081951A NO20081951L (no) 2005-09-28 2008-04-23 Milnacipran for langtidsbehandling av fibromyalgisyndrom

Country Status (24)

Country Link
US (1) US7994220B2 (no)
EP (2) EP1928446A4 (no)
JP (3) JP2009510080A (no)
KR (1) KR20080055967A (no)
CN (1) CN101355930A (no)
AU (1) AU2006294645B2 (no)
BR (1) BRPI0617541A2 (no)
CA (1) CA2624018A1 (no)
CR (1) CR9882A (no)
EC (1) ECSP088407A (no)
GE (1) GEP20125595B (no)
IL (2) IL190284A (no)
MA (1) MA31720B1 (no)
MY (1) MY145340A (no)
NI (1) NI200800099A (no)
NO (1) NO20081951L (no)
NZ (2) NZ593199A (no)
RU (1) RU2437661C2 (no)
SG (3) SG183735A1 (no)
SV (1) SV2008002855A (no)
TN (1) TNSN08129A1 (no)
UA (1) UA94721C2 (no)
WO (1) WO2007038620A2 (no)
ZA (1) ZA200803469B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20030203055A1 (en) * 2002-03-15 2003-10-30 Cypress Bioscience, Inc. Methods of treating visceral pain syndromes
EP1558231A4 (en) * 2002-10-03 2010-09-08 Cypress Bioscience Inc DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
TW200911225A (en) * 2007-05-22 2009-03-16 Cypress Bioscience Inc Methods for improving physical function in fibromyalgia
WO2009025091A1 (ja) * 2007-08-23 2009-02-26 St. Marianna University School Of Medicine 線維筋痛症治療用医薬組成物
JP5274071B2 (ja) * 2008-03-28 2013-08-28 旭化成ファーマ株式会社 線維筋痛症治療剤
WO2009139470A1 (ja) * 2008-05-16 2009-11-19 学校法人聖マリアンナ医科大学 線維筋痛症治療用医薬組成物
JP2012505238A (ja) 2008-10-08 2012-03-01 カイフィア ファーマシューティカルズ， インコーポレイテッド Ｇａｂａコンジュゲートおよびそれらの使用方法
US20100197797A1 (en) * 2009-02-05 2010-08-05 Rao Srinivas G Methods of managing fibromyalgia using milnacipran
ES2487616T3 (es) 2009-03-10 2014-08-22 Takeda Pharmaceutical Company Limited Derivados de benzofurano
US20100286260A1 (en) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Ltd. Milnacipran formulations
HUE037281T2 (hu) 2009-11-20 2018-08-28 Tonix Pharma Holdings Ltd Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US20120232159A1 (en) * 2011-03-07 2012-09-13 Tonix Pharmaceuticals, Inc. Methods and Compositions for Treating Depression using Cyclobenzaprine
FR2978350B1 (fr) 2011-07-28 2013-11-08 Pf Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
EA029151B1 (ru) * 2011-09-06 2018-02-28 Курна, Инк. ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АЛЬФА-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
US9636408B2 (en) 2013-03-15 2017-05-02 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
MX2017003644A (es) 2014-09-18 2017-10-31 Tonix Pharma Holdings Ltd Formulaciones eutecticas de clorhidrato de ciclobenzaprina.
WO2019116091A1 (en) 2017-12-11 2019-06-20 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010A (en) * 1845-04-22 Island
US3023A (en) * 1843-03-30 peters
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2508035A1 (fr) * 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
US4740198A (en) * 1981-10-09 1988-04-26 Alza Corporation Method of administering intravenous drug using rate-controlled dosage form
US4882167A (en) 1983-05-31 1989-11-21 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
US4571333A (en) * 1983-06-14 1986-02-18 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4849229A (en) * 1984-03-26 1989-07-18 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4781919A (en) 1984-06-18 1988-11-01 Schering Corporation Sustained release dosage form
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
DE3583799D1 (de) * 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
CA1270765A (en) * 1985-02-19 1990-06-26 Charles Hsiao Controlled release potassium chloride
GB8521494D0 (en) 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
IL78017A (en) * 1986-03-03 1989-06-30 Yissum Res Dev Co Sustained release tablets of theophylline
US4775535A (en) 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4708834A (en) 1986-05-01 1987-11-24 Pharmacaps, Inc. Preparation of gelatin-encapsulated controlled release composition
US4795642A (en) * 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4798725A (en) * 1986-06-16 1989-01-17 Norwich Eaton Pharmaceuticals, Inc. Sustained release capsule
US4710384A (en) 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US4816262A (en) * 1986-08-28 1989-03-28 Universite De Montreal Controlled release tablet
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
US4861590A (en) * 1986-09-25 1989-08-29 Colgate-Palmolive Company Sustained release fluoride and calcium composition
US4800083A (en) * 1986-10-20 1989-01-24 R. P. Scherer Corporation Sustained release method and product
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US4822619A (en) * 1987-02-18 1989-04-18 Ionor, Inc. Controlled release pharmaceutical preparation containing a gastrointestinal irritant drug
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US4806359A (en) * 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
US4792448A (en) 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
CA1323798C (en) * 1987-10-06 1993-11-02 Robert James Belanger Flakes of baking shortening or lard
FR2640972B1 (no) * 1988-12-28 1991-04-19 Pf Medicament
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
CA2041774C (en) 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US20020006963A1 (en) * 1992-06-23 2002-01-17 Young James W. Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
GB9215043D0 (en) 1992-07-15 1992-08-26 Flow Inc K Fluid mass flow meters
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5397574A (en) * 1993-10-04 1995-03-14 Andrx Pharmaceuticals, Inc. Controlled release potassium dosage form
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US5935060A (en) * 1996-07-12 1999-08-10 First Opinion Corporation Computerized medical diagnostic and treatment advice system including list based processing
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US5621142A (en) * 1994-02-22 1997-04-15 Asahi Kasei Kogyo Kabushiki Kaisha Aminoalkylcyclopropane derivatives
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
CA2185803C (en) * 1994-03-18 2006-07-11 Edward M. Rudnic Emulsified drug delivery systems
US5399362A (en) * 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5658955A (en) * 1994-11-01 1997-08-19 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of immune disorders
US6103263A (en) * 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
AU6776196A (en) 1995-08-16 1997-03-12 Eli Lilly And Company Potentiation of serotonin response
AU2587297A (en) * 1996-03-25 1997-10-17 Eli Lilly And Company Method for treating pain
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
EP0818198A1 (en) 1996-07-09 1998-01-14 Lilly S.A. Potentiation of drug response by increasing serotonin availability
FR2752732B1 (fr) 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
WO1998018452A1 (en) * 1996-10-25 1998-05-07 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
US5837379A (en) 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
EP0914098B1 (en) 1997-05-30 2003-10-01 Osmotica Corp. Multi-layered osmotic device
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
EP0919234A3 (en) * 1997-10-17 1999-08-25 Eli Lilly And Company Potentiation of pharmaceuticals by moxonidine
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
US5994363A (en) 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6489341B1 (en) 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US6573373B1 (en) 1999-06-29 2003-06-03 Isis Pharmaceuticals, Inc. High affinity, low molecular weight displacers for oligonucleotide purification
KR100935277B1 (ko) * 1999-07-01 2010-01-06 파마시아 앤드 업존 캄파니 엘엘씨 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
DE60021266T2 (de) * 1999-08-13 2006-05-24 L&L Technologies, Llc Verwendungen von Zusammensetzungen zur Behandlung oder Vorbeugung von Schlafstörungen unter Verwendung von sehr niedrigen Dosen von Cyclobenzaprin
US6610681B1 (en) * 1999-08-16 2003-08-26 Revaax Pharmaceuticals, Llc Neurotherapeutic clavulanate composition and method
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
US6380200B1 (en) * 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
WO2001062236A2 (en) * 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
GB2362826A (en) 2000-06-02 2001-12-05 Lilly Co Eli A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
CA2364211A1 (en) * 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
EP1353675A2 (en) 2001-01-02 2003-10-22 PHARMACIA & UPJOHN COMPANY New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
US20020147196A1 (en) 2001-04-05 2002-10-10 Quessy Steven Noel Composition and method for treating neuropathic pain
CZ20032764A3 (cs) 2001-04-19 2004-04-14 Warner-Lambert Company Fúzní bicyklické nebo tricyklické aminokyseliny
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
RU2187307C1 (ru) 2001-10-15 2002-08-20 Сыров Кирилл Константинович Твердые стабильные лекарственные формы преднизолона
US20030082225A1 (en) * 2001-10-19 2003-05-01 Mason Paul Arthur Sterile, breathable patch for treating wound pain
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
KR20050044604A (ko) * 2001-11-30 2005-05-12 일라이 릴리 앤드 캄파니 노르에피네프린 재흡수 억제제의 틱 장애 치료 용도
US20030143548A1 (en) * 2002-01-28 2003-07-31 Camilleri Michael L. Predicting patient responsiveness to serotonergic therapy
AU2003213009A1 (en) * 2002-02-12 2003-09-04 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
US20030203055A1 (en) 2002-03-15 2003-10-30 Cypress Bioscience, Inc. Methods of treating visceral pain syndromes
US20030232805A1 (en) 2002-04-24 2003-12-18 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
EP1558231A4 (en) * 2002-10-03 2010-09-08 Cypress Bioscience Inc DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20060024366A1 (en) * 2002-10-25 2006-02-02 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
AU2004207578B2 (en) 2003-01-28 2007-06-28 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US7787453B2 (en) * 2006-08-03 2010-08-31 Broadcom Corporation Network interface controller with receive side scaling and quality of service
US20080058317A1 (en) * 2006-08-09 2008-03-06 Cypress Bioscience, Inc. Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome
US20080058318A1 (en) * 2006-08-09 2008-03-06 Cypress Bioscience, Inc. Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia
TW200911225A (en) 2007-05-22 2009-03-16 Cypress Bioscience Inc Methods for improving physical function in fibromyalgia

Also Published As

Publication number Publication date
SG10201706677TA (en) 2017-09-28
ZA200803469B (en) 2009-02-25
CA2624018A1 (en) 2007-04-05
MY145340A (en) 2012-01-31
IL228904A0 (en) 2013-12-31
CR9882A (es) 2009-03-27
JP2009510080A (ja) 2009-03-12
IL228904A (en) 2016-08-31
JP6014702B2 (ja) 2016-10-25
EP2682114B1 (en) 2020-11-04
BRPI0617541A2 (pt) 2011-07-26
AU2006294645B2 (en) 2012-08-23
GEP20125595B (en) 2012-08-10
JP2012193216A (ja) 2012-10-11
NZ567271A (en) 2011-06-30
EP1928446A4 (en) 2010-08-25
NZ593199A (en) 2012-11-30
SG10201807899PA (en) 2018-10-30
RU2008112192A (ru) 2009-11-10
NI200800099A (es) 2012-08-17
JP5922515B2 (ja) 2016-05-24
ECSP088407A (es) 2008-06-30
US20070072946A1 (en) 2007-03-29
SV2008002855A (es) 2008-06-30
RU2437661C2 (ru) 2011-12-27
WO2007038620A3 (en) 2007-10-18
EP1928446A2 (en) 2008-06-11
UA94721C2 (en) 2011-06-10
TNSN08129A1 (en) 2009-07-14
CN101355930A (zh) 2009-01-28
AU2006294645A1 (en) 2007-04-05
EP2682114A1 (en) 2014-01-08
US7994220B2 (en) 2011-08-09
KR20080055967A (ko) 2008-06-19
IL190284A0 (en) 2009-09-22
WO2007038620A2 (en) 2007-04-05
IL190284A (en) 2014-01-30
JP2015134811A (ja) 2015-07-27
SG183735A1 (en) 2012-09-27
MA31720B1 (fr) 2010-10-01

Similar Documents

Publication Publication Date Title
NO20081951L (no) Milnacipran for langtidsbehandling av fibromyalgisyndrom
EA201370208A1 (ru) Формы рифаксимина и их применение
EA200970147A1 (ru) Получение (2r,3r)-3-(3-метоксифенил)-n,n,2-триметилпентанамина
NO20090376L (no) Fremgangsmate for fremstilling av (1R,2R)-3-(3-dimetylamino-1-etyl-2-metyl-propyl)-fenol
BR122012023120B8 (pt) Composto inibidor da recaptação de serotonina
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
BRPI0908421C1 (pt) solução estável de um composto farmacêutico
SE0502254L (sv) Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
EA200970946A1 (ru) Комбинированная терапия антикоагулирующего средства с соединением, которое действует как ингибитор фактора ха
NO20074238L (no) Fiksert dosering av HER-antistoffer
WO2010042163A3 (en) Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
EA200801897A1 (ru) Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений
EA201070451A1 (ru) Амидные соединения
EA200700909A1 (ru) Азаиндолкарбоксамиды
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
ATE524076T1 (de) Niedrig-glykämische mischungen
ME00996B (me) Trans-klomifen za liječenje metaboličkog sindroma
DK1694318T3 (da) (S)-2-N-propylamino-5-hydroxytetralin som D3-agonistisk terapeutikum
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
NO20075153L (no) Terapeutisk anvendelse av nefopam og analoger derav
EA201000633A1 (ru) КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ
CL2011001943A1 (es) Terapia antibiotica para tartar o prevenir el sindrome del intestino irritable post- infeccioso.
UY33354A (es) Compuesto biciclico como inhibidor acc
NO20090234L (no) Tricyklisk sammensetning og farmasoytisk anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application